Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2019-10-23 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于上海美迪西生物医药股份有限公司首次公开发行股票并在科创板上市之战略配售事项之专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed legal and compliance report from 广发证券股份有限公司 regarding the strategic placement (strategic配售) of shares in the initial public offering (IPO) of 上海美迪西生物医药股份有限公司 on the 科创板 (Science and Technology Innovation Board). It includes extensive information about the approval process, strategic investors, their qualifications, compliance with regulatory rules, and legal opinions from a law firm. The document references specific regulatory rules and guidelines related to securities issuance and underwriting, and it is focused on the verification and compliance of strategic investors in the IPO process. It is not a financial report, earnings release, or general announcement but a specialized audit or verification report related to the IPO's strategic placement. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting or regulatory compliance information related to securities issuance. FY 2019
2019-10-23 Chinese
首次公开发行股票并在科创板上市投资风险特别公告
Regulatory Filings
2019-10-23 Chinese
首次公开发行股票并在科创板上市网上路演公告
Investor Presentation Classification · 90% confidence The document is an announcement regarding the initial public offering (IPO) of Shanghai Medicilon Inc. on the STAR Market (科创板). It details the offering size, pricing mechanism, allocation between strategic investors, offline and online investors, and the schedule for an online roadshow. The document does not contain financial statements or detailed financial analysis but serves to inform investors about the IPO process and the upcoming investor presentation event. It is not the actual investor presentation but an announcement of the roadshow event. Given the content and length (1024 characters), this fits best as an Investor Presentation (IP) type document, as it focuses on financial and strategic information for investors related to the IPO.
2019-10-22 Chinese
附件1美迪西首次公开发行股票并在科创板上市招股意向书附录（一）
Regulatory Filings
2019-10-16 Chinese
首次公开发行股票并在科创板上市招股意向书
Capital/Financing Update Classification · 95% confidence The document is a 招股意向书 (Prospectus or Offering Intention Document) for an initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market (科创板). It includes detailed information about the stock issuance, risk factors, company background, governance, financial data, and other disclosures typical of an IPO prospectus. The document is lengthy (15,000 characters) and contains substantive financial and business information, not merely an announcement or a brief summary. It is not an Annual Report, Earnings Release, or any other category but fits best as a Capital/Financing Update (CAP) because it relates to the company's fundraising and capital issuance activities through an IPO. Therefore, the appropriate classification is CAP with high confidence.
2019-10-16 Chinese
附件2美迪西首次公开发行股票并在科创板上市招股意向书附录（二）
Regulatory Filings
2019-10-16 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.